表柔比星灌注预防浅表性膀胱癌术后复发

目的 评价表柔比星(EPI)膀胱内灌注预防浅表性膀胱癌术后复发的疗效和安全性。方法 对63例浅表性膀胱癌患者行经尿道膀胱肿瘤电切术(TuRBt)或膀胱部分切除术，术后定期应用EPl30mg(40mL)作膀胱内灌注，每周1次，共8次，以后每月1次，共1年。每次药物在膀胱内保留l小时。结果 经7～28月随访，平均15月，复发4例，复发率为6.3％，未见全身性药物不良反应，仅5例出现轻度膀胱刺激症状。结论 EPI膀胱内灌注预防浅表性膀胱癌术后复发疗效满意，副作用轻，耐受性良好。

Intravesical instillation of epirubicin for preventing postoperative recurrence of superficial bladder cancer

AIM To evaluate intravesical instilliation of epirubicin (EPI) for the prevention of postoperative recurrence of bladder cancer. METHOD Transurethral resection or partial cystectomy was performed on 63 patients with superficial bladder cancer, followed by EPI intravesical instillation once a week for 8 weeks and then once a month until 1 year after surgery. RESULTS All patients have been followed-up for 7 to 28 months. It showed that tumor recurrence occurred only in 4 patients(6.3%). No systemic adverse reaction has been observed, and only 5 patients have transitory bladder irritation. CONCLUSION Postoperative intravesical instillation of EPI for superficial bladder cancer has good prophylactic effects on the recurrence with least side effects.